Efficacy and Safety of Vedolizumab in Management of Moderate to Severe Ulcerative Colitis: A Systematic Review

Ulcerative colitis (UC) is an inflammatory bowel disease and causes inflammation and ulcer of the colon. Vedolizumab is a newer biological agent with an inhibitory effect on α4β7 integrin approved for moderate to severe UC patients. Our study reviewed the clinical response, clinical remission, and m...

Descripción completa

Detalles Bibliográficos
Autores principales: Bhandari, Renu, Ogeyingbo, Opemipo D, Kareem, Roaa, Gyawali, Mallika, Venkatesan, Nanditha, Ahmed, Rowan, Botleroo, Rinky A, Elshaikh, Abeer O
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2021
Materias:
Internal Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8491799/
https://www.ncbi.nlm.nih.gov/pubmed/34659943
http://dx.doi.org/10.7759/cureus.17729

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8491799/
https://www.ncbi.nlm.nih.gov/pubmed/34659943
http://dx.doi.org/10.7759/cureus.17729

Ejemplares similares